 The FDA has signed off Sorrento Therapeutics Incs NASDAQ: SRNE Phase 1 study of its oral main viral protease Mpro inhibitor, STI-1558, in patients with impaired renal and hepatic function. The Phase 1 study will examine the PK in patients with moderate renal and. 